Side-by-side comparison
Anamorelin vs Pentadeca Arginate (PDA)
Oral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz. versus Arginate-salt analog of BPC-157 developed for improved injection stability and tissue repair.
Anamorelin
PerformanceOral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.
Top benefits
- ✓Increases lean body mass
- ✓Improves appetite
- ✓Oral bioavailability
Pentadeca Arginate (PDA)
RecoveryArginate-salt analog of BPC-157 developed for improved injection stability and tissue repair.
Top benefits
- ✓Tendon and ligament healing
- ✓Better stability than BPC-157 acetate
- ✓Anti-inflammatory
| Attribute | Anamorelin | Pentadeca Arginate (PDA) |
|---|---|---|
| Category | Performance | Recovery |
| Type | small-molecule | linear |
| Chain length | 1 aa | 15 aa |
| Formula | C31H42N6O3 | BPC-157 arginate salt |
| Common dose | 100 mg | 250-500 mcg |
| Frequency | Daily, oral | 1-2x daily SC |
| Top benefit | Increases lean body mass | Tendon and ligament healing |
| Top side-effect | Hyperglycemia | Injection-site irritation |
⚠
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.